• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alvogen recalls fentanyl patches over 3M labeling error

April 23, 2019 By Danielle Kirsh

alvogen-logoAlvogen announced that it is voluntarily recalling two of its Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level because of a labeling issue.

The company says that a small number of cartons that were labeled as 12 mcg/h Fentanyl Transdermal System patches actually had 50 mcg/h patches. The 50 mcg/h patches in the cartons were labeled as such. The transdermal system is made by 3M Drug Delivery Systems.

If a higher dose of the Fentanyl Transdermal System is used instead of the 12 mcg/h patch, it could result in more serious, life-threatening or fatal respiratory depression. First time recipients, children and the elderly are most at risk. Alvogen has so far not received any reports of adverse effects because of the mislabeling.

Alvogen’s Fentanyl Transdermal System is designed for managing pain in patients who are opioid-tolerant. It is packaged in cartons of five individually wrapped and labeled pouches.

The two lots being recalled are Lot 180060 of Fentanyl Transdermal System, 12 mcg/h, expiration date 05/2020 and Lot 180073 of Fentanyl Transdermal System, 12 mcg/h, expiration date 06/2020.

The Fentanyl Transdermal System was distributed across the U.S. to the pharmacy level and is packaged in a 12 mcg/h primary carton.

Alvogen is in the process of notifying distributors and direct customers through a certified letter of the recall and is arranging for returns and replacement of the recalled patches. Pharmacies have been told not to dispense any of the products related to the recall and patients who have the patches should remove any patch that is currently in use and contact their healthcare providers.

Filed Under: Recalls Tagged With: alvogen

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS